Closed Bioreactor for Autologous T Cell Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current manufacturing processes for autologous T-cell therapeutics are labor-intensive, costly, and inefficient, with challenges including contamination risk, high facility footprint, and donor-to-donor variability, which hinder the scalability and affordability of genetically engineered autologous T cells for clinical use.
Innovation Solution
A method involving the use of a closed single-use bioreactor bag within a rocking bioreactor platform for the production of genetically engineered autologous T cells. This method includes inoculating the bioreactor with apheresed donor cells and soluble T cell activators, followed by continuous rocking during cell culture, transduction with a viral vector, and expansion, allowing for increased cell density and reduced manual handling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional manual manufacturing processes are used for autologous T-cell therapeutics, then flexibility in handling donor variability is maintained, but labor intensity and production costs increase significantly
Solution Approach 1:
The patent implements automated cell processing with controlled parameters including temperature (37°C), CO2 levels (5%), and automated media exchange intervals. The system uses standardized protocols for cell activation, transduction, and expansion that can accommodate different donors while reducing manual labor through automation
Solution Approach 2:
The bioreactor system performs self-service functions including automated media exchange, temperature regulation, and cell monitoring. The system automatically maintains optimal culture conditions and performs routine tasks without continuous manual intervention, reducing labor intensity while maintaining adaptability to donor variability
2Ease of operation
If traditional open manufacturing systems are used, then process flexibility is maintained, but contamination risk increases
Solution Approach 1:
The patent employs a closed bioreactor system that maintains a sterile, controlled environment for cell culture. The system uses sterile filters, sealed culture vessels, and controlled atmospheric conditions to prevent contamination while maintaining process flexibility through automated operations
Solution Approach 2:
The system uses disposable sterile culture vessels and single-use bioreactor bags that eliminate the need for extensive sterilization procedures. These single-use components reduce contamination risk while maintaining ease of operation through simple setup and disposal protocols
3Productivity
If large-scale production facilities are established, then commercial quantities can be produced, but facility footprint and capital investment increase
Solution Approach 1:
The patent employs modular bioreactor systems that can be configured in parallel to produce commercial quantities of T-cells. Each modular unit operates independently, allowing scalable production without requiring proportionally larger facility footprints. The segmented approach enables flexible production capacity adjustment
Solution Approach 2:
The system transitions from traditional horizontal facility expansion to vertical stacking of bioreactor modules. Multiple bioreactors can be stacked or arranged in three-dimensional configurations, increasing production capacity while minimizing footprint utilization
4Manufacturing precision
If multiple manual handling steps are performed, then process control is maintained, but production time and cost increase
Solution Approach 1:
The patent implements continuous cell culture and expansion processes within the bioreactor system. Cell activation, transduction, and expansion occur in continuous culture rather than batch processing, eliminating manual transfer steps between vessels and reducing production time while maintaining process control through automated monitoring
Solution Approach 2:
The system merges multiple process steps including cell activation, transduction, and expansion into a single integrated bioreactor platform. This consolidation eliminates intermediate handling steps and reduces production time while maintaining manufacturing precision through unified process control
Data Source
AI summary
The present invention relates to production of autologous genetically engineered T cells for use in cell therapy applications.